Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Net Margin (2018 - 2025)

Sunshine Biopharma's Net Margin history spans 8 years, with the latest figure at 24.96% for Q4 2025.

  • For Q4 2025, Net Margin fell 247.0% year-over-year to 24.96%; the TTM value through Dec 2025 reached 16.46%, up 194.0%, while the annual FY2025 figure was 16.46%, 174.0% down from the prior year.
  • Net Margin reached 24.96% in Q4 2025 per SBFM's latest filing, down from 3.14% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 783.75% in Q4 2021 to a low of 15440.43% in Q1 2021.
  • Average Net Margin over 5 years is 1569.91%, with a median of 23.73% recorded in 2025.
  • The largest YoY upside for Net Margin was 1443245bps in 2022 against a maximum downside of -138054bps in 2022.
  • A 5-year view of Net Margin shows it stood at 783.75% in 2021, then tumbled by -176bps to 596.78% in 2022, then skyrocketed by 97bps to 16.28% in 2023, then plummeted by -38bps to 22.49% in 2024, then decreased by -11bps to 24.96% in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Net Margin are 24.96% (Q4 2025), 3.14% (Q3 2025), and 31.36% (Q2 2025).